Bio-Path Investor Relations Material
Latest events
Status Update
Bio-Path
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Bio-Path Holdings Inc
Access all reports
Bio-Path Holdings Inc. is a biotechnology company focused on the development of RNAi-based therapies for cancer treatment. The company uses its proprietary DNAbilize® platform to design lipid-delivered RNAi therapeutics that target specific proteins involved in cancer cell survival and proliferation. Bio-Path’s lead programs focus on treating hematologic cancers such as leukemia and lymphoma. The company’s approach aims to provide innovative treatment options for patients with unmet medical needs in oncology. The company is headquartered in Bellaire, Texas, USA, and its shares are listed on the NASDAQ.
Latest articles
)
The Dilemma That Brought Down Kodak
Kodak helped invent digital photography but failed to embrace it. How the innovator's dilemma turned an icon into its own most famous casualty.
21 Aug 2025
)
Maziar Mike Doustdar: Novo Nordisk's New CEO
A portrait of the pharmaceutical giant's new CEO, who assumes the position at a critical time for the company in its competition with Eli Lilly.
12 Aug 2025
)
Novo Nordisk: Tipping the Scale of Innovation
Taking a look at the company behind Ozempic and Wegovy and diving into their history, business, and the challenges it now faces
8 Aug 2025
Ticker symbol
BPTH
Country
🇺🇸 United States